Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
Study Results
Related Studies
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
This study has been terminated.
( Study stopped because of toxicity concerns. )
Study NCT00393380 Information provided by The EMMES Corporation
First Received on October 25, 2006. Last Updated on April 22, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia, Myeloid, Chronic
Anemia, Aplastic
Myelofibrosis
Lymphoma
Hodgkin Disease
Leukemia, Lymphocytic, Chronic
Leukemia, Myelocytic, Acute
Leukemia, Lymphocytic, Acute
Additional conditions recognized in this trial
Anemia
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Primary Myelofibrosis
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Immune System Diseases
Immunoproliferative Disorders
Leukemia, B-Cell
Lymphatic Diseases
Lymphoproliferative Disorders
Myeloproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Parathyroid Hormone (teriparatide)
Additional drug interventions recognized in this trial
Hormones
Teriparatide
More general drug interventions related to this trial
Bone Density Conservation Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
The EMMES Corporation
National Heart, Lung, and Blood Institute (NHLBI)
Back to top of Main Content
